Ongoing Clinical Trials for Retroperitoneal Cancer
Currently, there is 1 ongoing clinical trial exploring treatment options for patients with retroperitoneal cancer, specifically focusing on advanced ovarian, fallopian tube, and peritoneal cancers. This trial is investigating the combination of Olaparib and Bevacizumab following standard first-line chemotherapy and is being conducted in Spain.
Clinical trial locations
Study on Olaparib and Bevacizumab for Patients with Advanced Ovarian, Fallopian Tube, or Peritoneal Cancer
This clinical trial is designed for women with advanced stages of ovarian cancer, fallopian tube cancer, or peritoneal cancer, classified as FIGO Stage III-IV high-grade serous or endometrioid cancers. The study explores the potential benefits of combining two medications after patients have completed their standard first-line treatment.
Who can participate?
The trial is open to women who meet several specific criteria. Participants must be at least 18 years old and have a newly diagnosed advanced stage of high-grade serous or endometrioid cancer affecting the ovaries, peritoneum, or fallopian tubes. They must have already completed at least 6 cycles of platinum-taxane chemotherapy and at least 3 cycles of Bevacizumab as their first-line treatment. To join the study, participants need to show no signs of disease progression or be in complete or partial response to their initial treatment, meaning the cancer has not gotten worse.
Additionally, eligible participants must have an ECOG performance status of 0-1, which indicates they are either fully active or have some symptoms but can still carry out light work. They need a life expectancy of at least 16 weeks and must be post-menopausal or have a negative pregnancy test if still of childbearing age. Normal organ and bone marrow function is required, including specific levels of hemoglobin, white blood cells, platelets, and proper liver and kidney function. A sample of the original tumor tissue must also be available for testing.
Who cannot participate?
The trial excludes patients who have other types of cancer not specified in the study, those who have not been diagnosed with the specific cancer stages mentioned, and individuals who do not meet the required age or gender criteria. Patients considered part of a vulnerable population requiring special protection or care are also excluded from participation.
What is the goal of the trial?
The main focus of this study is to better understand how the combination of Olaparib and Bevacizumab can benefit patients after they have received standard first-line treatment. Researchers are particularly interested in exploring something called HRD status, which stands for homologous recombination deficiency. This refers to a condition where cancer cells are less able to repair damage to their DNA, which can affect how well they respond to certain treatments.
The study aims to determine how well different tests can identify HRD status and how this status affects treatment outcomes. Participants will be monitored regularly to assess progression-free survival, which means how long they live without the cancer getting worse, as well as overall survival. The trial will also carefully track any side effects experienced during treatment. The study is expected to continue until 2028.
What medications are being tested?
The trial involves two investigational drugs: Olaparib and Bevacizumab. Olaparib, also known by its code name AZD-2281, is a medication that blocks an enzyme called PARP, which helps cancer cells repair their DNA. By preventing this repair process, Olaparib can cause cancer cells to die. It is taken orally in tablet form, typically twice daily.
Bevacizumab, sometimes referred to by code names such as BI 695502 or RHUMAB-VEGF, is a type of antibody that works differently. It blocks the growth of new blood vessels that tumors need to receive nutrients and grow. By cutting off this blood supply, Bevacizumab can help slow down or stop cancer growth. This medication is given through intravenous infusion every three weeks.
Both medications are being used together in this trial to see if their combined effect provides additional benefits compared to standard treatments alone. Throughout the study, participants will receive regular monitoring, including blood tests, imaging assessments, and evaluations of vital signs to track how well the treatment is working and identify any side effects.
Summary
Currently, only one clinical trial is actively recruiting patients with advanced peritoneal, ovarian, or fallopian tube cancers, with the study taking place in Spain. This trial focuses on the combination therapy of Olaparib and Bevacizumab following completion of standard chemotherapy. A notable aspect of this research is its emphasis on understanding HRD status and how it influences treatment response, which could help personalize cancer care in the future. The trial represents an important step in exploring maintenance treatment strategies for patients who have responded to initial chemotherapy, with results expected by 2028.
